See more : PAOS INDUSTRIES LIMITED (PAOS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Alto Neuroscience, Inc. (ANRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alto Neuroscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Rajasthan Tube Manufacturing Company Limited (RAJTUBE.BO) Income Statement Analysis – Financial Results
- Tanaken (1450.T) Income Statement Analysis – Financial Results
- Daxin Materials Corporation (5234.TW) Income Statement Analysis – Financial Results
- Shenzhen INVT Electric Co.,Ltd (002334.SZ) Income Statement Analysis – Financial Results
- Hadasit Bio-Holdings Ltd (HSITF) Income Statement Analysis – Financial Results
Alto Neuroscience, Inc. (ANRO)
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 210.00K |
| Cost of Revenue | 373.00K | 342.00K | 145.00K |
| Gross Profit | -373.00K | -342.00K | 65.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 30.95% |
| Research & Development | 30.29M | 23.69M | 8.37M |
| General & Administrative | 7.52M | 5.50M | 3.90M |
| Selling & Marketing | 0.00 | -342.00K | -145.00K |
| SG&A | 7.52M | 5.16M | 3.75M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.81M | 28.85M | 12.12M |
| Cost & Expenses | 37.81M | 29.19M | 12.27M |
| Interest Income | 2.35M | 114.00K | 2.00K |
| Interest Expense | 1.37M | 0.00 | 0.00 |
| Depreciation & Amortization | 373.00K | 342.00K | 145.00K |
| EBITDA | -34.56M | -27.37M | -9.04M |
| EBITDA Ratio | 0.00% | 0.00% | -5,671.90% |
| Operating Income | -37.81M | -29.19M | -12.06M |
| Operating Income Ratio | 0.00% | 0.00% | -5,740.95% |
| Total Other Income/Expenses | 1.50M | 1.48M | 2.87M |
| Income Before Tax | -36.31M | -27.71M | -9.19M |
| Income Before Tax Ratio | 0.00% | 0.00% | -4,374.76% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 |
| Net Income | -36.31M | -27.71M | -9.19M |
| Net Income Ratio | 0.00% | 0.00% | -4,374.76% |
| EPS | -1.35 | -1.08 | -0.36 |
| EPS Diluted | -1.35 | -1.08 | -0.36 |
| Weighted Avg Shares Out | 26.88M | 25.57M | 25.57M |
| Weighted Avg Shares Out (Dil) | 26.88M | 25.57M | 25.57M |
The Schall Law Firm Encourages Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Encouraged To Reach Out To The Schall Law Firm
The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Requests Stockholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
Source: https://incomestatements.info
Category: Stock Reports